कंपनी का अवलोकन
Supernus Pharmaceuticals, Inc. operates as a biopharmaceutical entity focused on the development and commercialization of therapeutic products designed to address central nervous system (CNS) diseases within the United States market. The company is situated within the Healthcare sector and specifically functions in the Drug Manufacturers - Specialty & Generic industry, indicating its specialization in niche pharmaceutical formulations rather than broad-spectrum mass production. Supernus maintains a substantial operational scale with a total market capitalization of $2.97B, an annual revenue of $718.95M, and a workforce comprising 778 employees. These valuation and revenue figures suggest that the company holds a significant position in its specialized niche, possessing sufficient market weight to sustain extensive research and commercialization efforts while maintaining a large employee base to support its product pipeline.
वित्तीय स्वास्थ्य
The company reported a revenue of $718.95M over the trailing twelve months, yet it posted a net income of -$38.55M and an EBITDA of $44.40M. The substantial gap between the positive revenue and the negative net income reveals a cost structure where expenses, likely driven by research and development or operational overhead, significantly erode the bottom line before taxes. Despite the net loss, the company generated $55.72M in free cash flow, which indicates a strong capacity to fund operations, service debt, and invest in growth initiatives without relying solely on external capital markets. The gross margin stands at 89.6%, reflecting the high value added by the company's proprietary formulations relative to the cost of goods sold. However, the operating margin is -28.9% and the profit margin is -5.4%, signaling that high fixed costs are currently preventing the company from converting revenue into operational profitability. The balance sheet shows a cash position of $308.67M against total debt of $40.98M, resulting in a debt-to-equity ratio of 3.86, which suggests a leveraged capital structure reliant on equity financing rather than debt. While the leverage is high, the current ratio of 1.91 indicates robust short-term liquidity, demonstrating that the company holds nearly double the liquid assets required to cover its immediate liabilities. Furthermore, the return on equity is -3.7% and the return on assets is -2.1%, revealing that management is currently generating negative returns on the capital invested by shareholders and the asset base.
मूल्यांकन आकलन
The valuation metrics present a complex picture with a trailing P/E ratio listed as N/A due to the net loss, while the forward P/E is 12.23. The disparity between the unavailable trailing multiple and the forward multiple implies that the market expects a significant turnaround in earnings trajectory to achieve profitability in the coming fiscal periods. The price-to-book ratio is 2.79, suggesting that the market values the company at a substantial premium over its net asset book value, likely reflecting the intangible value of its intellectual property and pipeline. Additionally, the price-to-sales ratio is 4.13 and the EV/EBITDA is 60.91, which are alternative metrics used to value growth-oriented biopharmaceutical firms where traditional earnings multiples are distorted by temporary losses. The stock's trading range over the last year has seen a high of $59.68 and a low of $29.16. Assuming the current price is derived from the forward P/E context, the valuation sits within a range that reflects market anticipation of future earnings recovery rather than current performance. The beta value is 0.73, indicating that the stock price exhibits lower volatility relative to the broader market, moving less aggressively than the overall index during periods of market fluctuation.
Growth & Income
Supernus Pharmaceuticals demonstrated a revenue growth rate of 21.5% year-over-year, while the earnings growth rate is N/A due to the current net loss position. Since earnings are not currently growing at a positive rate, the revenue expansion implies that top-line growth is not yet translating into bottom-line profitability, a common phase in the development cycle of specialty drug manufacturers. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders but instead retains earnings to reinvest into research, development, and commercial expansion. This strategy prioritizes long-term product pipeline growth and market penetration over immediate income distribution to investors. The overall growth and income profile is characterized by strong top-line expansion supported by positive free cash flow, despite the absence of current earnings growth and dividend payouts.